← All candidates
5 insider filings on record.
12 filings on record.
JBIOJade Biosciences, Inc.
NasdaqCM · Healthcare · $1.14B
$17.89
-6.53% · Sep 11
5 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what JBIO ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.14B
Float
52.0M
82% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$50.13 avg target
+180.2% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q2 '26−$0.76 act−$0.22
Q1 '26−$0.57 act−$0.09
Q3 '25−$0.48 act+$0.19
Coverage
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?Insider Monkey · 06-30Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsMarketBeat · 06-02Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In GrowthSimply Wall St. · 03-28Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
The file stays open
12 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice